James Clemmer on regulatory strategy
From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer · · IEEE EMBS
“I wish I was bolder sooner. I wish I moved faster sooner. The example here at Angio which became real when I joined the company the nano knife project was really focused on treating people with pancreatic cancer... we had to kind of shift gears and said, 'Okay, guys, we'll do what we can.' We developed a registry approach and we're going to share that data soon to the world to show we think we can do to help those patients open up access to a new form of care.”
On , James Clemmer, Chief Executive Officer, President & Director at ANGIODYNAMICS INC, spoke about regulatory strategy during IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer on IEEE EMBS.
About James Clemmer
In a December 2025 interview with IEEE Pulse, AngioDynamics CEO Jim Clemmer discussed the company's transformation into a science-driven MedTech innovator focused on cancer and cardiovascular disease. Clemmer described the company's strategy of active portfolio management, stating, "It took active portfolio management, which is easy to say, hard to do. So, we divested some assets that actually provided revenue and profit for the company." He also highlighted the company's market performance, saying, "Now five years post launch, we're already taking a number three position in market share, past three of those really big powerful companies." Clemmer emphasized the importance of physician collaboration, clinical evidence, and early reimbursement strategy in bringing breakthrough medical technologies to market. He noted that AngioDynamics obtained a CPT-1 code before receiving 510K clearance, which he described as unusual in his experience. Clemmer also discussed the challenges of market access, stating, "Market access can be really, really challenging and teams need to really think that through and have a really good strategy." He shared his background starting as a sales representative in 1989 and described how the company engaged with physicians to build trust and support for its products.